Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BL-1020, improves deficits in preclinical paradigms assessing performance in two distinct cognitive domains
Subscribe to our email newsletter
BioLineRx has reported new results confirming its GABA enhanced BL-1020 drug’ MOA.
BL-1020 is an orally available antipsychotic for the treatment of schizophrenia. BL-1020 has recently completed a phase 2b clinical trial, designed to provide evidence that BL-1020 is a new generation antipsychotic with minimal side effects and greater tolerability.
Recent pre-clinical studies show that BL-1020 reverses cognitive impairment and that this reversal is mediated by the GABA moiety of BL-1020.
Morris Laster, CEO, BioLineRx, said: “These results are extremely important for the confirmation of the mode of action of BL-1020 in reducing EPS and improving cognition.
“These results showing improved cognition may also allow for increased indication coverage for BL-1020 including dementia associated with Parkinson’s and even as a potential adjunct treatment for Alzheimer’s, he added.